1.1M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 1,540,000 | 1,540,000 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 440,000 | 440,000 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 638,000 | 638,000 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 440,000 | 440,000 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 572,000 | 572,000 | - | - | Stock Option (Right to Buy) | |
| Robert Paul Smith | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 572,000 | 572,000 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.66 per share. | 24 Jun 2024 | 1,908 | 196,891 (0%) | 0% | 0.7 | 1,260 | Common Stock |
| Faheem Hasnain | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.67 per share. | 21 Jun 2024 | 372,000 | 5,408,073 (8%) | 0% | 0.7 | 250,282 | Common Stock |
| Bryan Giraudo | COO/CFO | Purchase of securities on an exchange or from another person at price $ 0.59 per share. | 18 Jun 2024 | 100,000 | 480,010 (0%) | 0% | 0.6 | 59,110 | Common Stock |
| Robert Paul Smith | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 0.60 per share. | 17 Jun 2024 | 25,000 | 25,000 (0%) | 0% | 0.6 | 15,050 | Common Stock |
| Russell J. Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 115,000 | 115,000 | - | - | Non-qualified stock option (Right to Buy) | |
| Thomas O. Daniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 115,000 | 115,000 | - | - | Non-qualified stock option (Right to Buy) | |
| John D. Quisel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 115,000 | 115,000 | - | - | Non-qualified stock option (Right to Buy) | |
| Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 115,000 | 115,000 | - | - | Non-qualified stock option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Sale of securities on an exchange or to another person at price $ 1.16 per share. | 27 Mar 2024 | 6,430 | 92,737 (0%) | 0% | 1.2 | 7,431 | Common Stock |
| Hasnain Faheem | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.16 per share. | 27 Mar 2024 | 23,172 | 120,293 (0%) | 0% | 1.2 | 26,773 | Common Stock |
| Waage Christian | EVP, Tech Ops and Admin | Sale of securities on an exchange or to another person at price $ 1.16 per share. | 27 Mar 2024 | 6,430 | 585,934 (0%) | 0% | 1.2 | 7,430 | Common Stock |
| Caryn Peterson | EVP, Regulatory Affairs | Sale of securities on an exchange or to another person at price $ 1.33 per share. | 18 Mar 2024 | 4,018 | 49,833 (0%) | 0% | 1.3 | 5,343 | Common Stock |
| Richard Aranda | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.33 per share. | 18 Mar 2024 | 4,018 | 198,799 (0%) | 0% | 1.3 | 5,342 | Common Stock |
| Skye Drynan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 230,000 | 230,000 | - | - | Stock Option (Right to Buy) | |
| Steven Nathan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 230,000 | 230,000 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 487,500 | 487,500 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 375,000 | 375,000 | - | - | Stock Option (Right to Buy) | |
| Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,312,500 | 1,312,500 | - | - | Stock Option (Right to Buy) | |
| Giraudo Bryan | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 543,750 | 543,750 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 375,000 | 375,000 | - | - | Stock Option (Right to Buy) | |
| Paul Smith Robert | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2023 | 1,500,000 | 1,500,000 | - | - | Stock Option (Right to Buy) | |
| Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 1.82 per share. | 24 Jul 2023 | 540,176 | 5,036,073 (8%) | 0% | 1.8 | 983,120 | Common Stock |
| Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 135,044 | 135,044 | - | - | Common Stock Purchase Warrants | |
| Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 1.82 per share. | 24 Jul 2023 | 13,504 | 45,892 (0%) | 0% | 1.8 | 24,577 | Common Stock |
| Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 3,376 | 3,376 | - | - | Common Stock Purchase Warrants | |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 13,505 | 13,505 | - | - | Common Stock | |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 1.82 per share. | 24 Jul 2023 | 54,020 | 180,010 (0%) | 0% | 1.8 | 98,316 | Common Stock |
| Richard Aranda | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.29 per share. | 22 Jun 2023 | 1,814 | 197,574 (0%) | 0% | 1.3 | 2,340 | Common Stock |
| Russell J. Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Thomas O. Daniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Kristina M. Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Renee D. Gala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 750,000 | 750,000 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 126,667 | 126,667 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP, Tech Ops and Admin | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 105,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP, Tech Ops and Admin | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 71,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP, Tech Ops and Admin | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 90,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP, Tech Ops and Admin | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 190,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 47,667 | 47,667 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 71,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 145,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 90,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 150,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 265,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 96,667 | 96,667 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 47,667 | 47,667 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 176,667 | 176,667 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 126,667 | 126,667 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 21,167 | 21,167 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 18,834 | 18,834 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 22,784 | 22,784 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 32,334 | 32,334 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 48,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 13,750 | 0 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 34,175 | 0 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 28,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 31,750 | 0 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 190,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 9,167 | 9,167 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 126,667 | 126,667 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 45,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 13,750 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 34,175 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 60,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 May 2023 | 190,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 9,167 | 9,167 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 22,784 | 22,784 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Purchase of securities on an exchange or from another person at price $ 1.02 per share. | 04 Apr 2023 | 55,000 | 125,990 (0%) | 0% | 1.0 | 56,095 | Common Stock |
| Faheem Hasnain | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.20 per share. | 20 Mar 2023 | 269,389 | 4,055,397 (6%) | 0% | 1.2 | 322,324 | Common Stock |
| Faheem Hasnain | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.14 per share. | 20 Mar 2023 | 440,500 | 4,495,897 (7%) | 0% | 1.1 | 503,580 | Common Stock |
| Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2023 | 544,500 | 544,500 | - | - | Stock Option (Right to Buy) | |
| Faheem Hasnain | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.03 per share. | 20 Mar 2023 | 168,683 | 3,786,008 (6%) | 0% | 1.0 | 174,486 | Common Stock |
| Christian Waage | EVP, Tech Ops and Admin | Purchase of securities on an exchange or from another person at price $ 1.20 per share. | 20 Mar 2023 | 18,500 | 32,388 (0%) | 0% | 1.2 | 22,145 | Common Stock |
| Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2023 | 157,500 | 157,500 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2023 | 211,500 | 211,500 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 20 Mar 2023 | 50,000 | 70,990 (0%) | 0% | 1.0 | 48,435 | Common Stock |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2023 | 157,500 | 157,500 | - | - | Stock Option (Right to Buy) | |
| Laura Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2023 | 157,500 | 157,500 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2023 | 157,500 | 157,500 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Sale of securities on an exchange or to another person at price $ 1.10 per share. | 16 Mar 2023 | 7,564 | 53,851 (0%) | 0% | 1.1 | 8,305 | Common Stock |
| Laura Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.10 per share. | 16 Mar 2023 | 6,029 | 76,263 (0%) | 0% | 1.1 | 6,620 | Common Stock |
| Richard Aranda | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.10 per share. | 16 Mar 2023 | 7,563 | 199,388 (0%) | 0% | 1.1 | 8,304 | Common Stock |
| Caryn Peterson | EVP, Regulatory Affairs | Sale of securities on an exchange or to another person at price $ 12.07 per share. | 24 Oct 2022 | 4,757 | 61,415 (0%) | 0% | 12.1 | 57,431 | Common Stock |
| Laura Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.07 per share. | 24 Oct 2022 | 4,876 | 82,292 (0%) | 0% | 12.1 | 58,868 | Common Stock |
| Richard Aranda | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.07 per share. | 24 Oct 2022 | 4,757 | 205,430 (0%) | 0% | 12.1 | 57,431 | Common Stock |
| Faheem Hasnain | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 7.21 per share. | 15 Jul 2022 | 138,696 | 3,617,325 (5%) | 0% | 7.2 | 999,998 | Common Stock |
| Christian Waage | EVP, Tech Ops and Admin | Purchase of securities on an exchange or from another person at price $ 7.21 per share. | 15 Jul 2022 | 6,934 | 13,888 (0%) | 0% | 7.2 | 49,994 | Common Stock |
| Bryan Giraudo | COO/CFO | Purchase of securities on an exchange or from another person at price $ 7.21 per share. | 15 Jul 2022 | 13,869 | 20,990 (0%) | 0% | 7.2 | 99,995 | Common Stock |
| Laura Carter | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 7.21 per share. | 15 Jul 2022 | 6,934 | 87,168 (0%) | 0% | 7.2 | 49,994 | Common Stock |
| Laura Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.25 per share. | 01 Jul 2022 | 8,808 | 80,234 (0%) | 0% | 8.2 | 72,648 | Common Stock |
| Richard Aranda | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.88 per share. | 22 Jun 2022 | 1,778 | 209,897 (0%) | 0% | 6.9 | 12,233 | Common Stock |
| Russell J. Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Thomas O. Daniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Kristina M. Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Joshua H. Bilenker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Renee D. Gala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Laura Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.20 per share. | 04 May 2022 | 1,262 | 89,042 (0%) | 0% | 7.2 | 9,086 | Common Stock |
| Faheem Hasnain | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 8.91 per share. | 23 Mar 2022 | 19,035 | 143,465 (0%) | 0% | 8.9 | 169,697 | Common Stock |
| Christian Waage | EVP, Tech Ops and Admin | Sale of securities on an exchange or to another person at price $ 8.92 per share. | 23 Mar 2022 | 10,722 | 579,008 (0%) | 0% | 8.9 | 95,587 | Common Stock |
| Bryan Giraudo | COO/CFO | Sale of securities on an exchange or to another person at price $ 8.92 per share. | 23 Mar 2022 | 10,722 | 99,167 (0%) | 0% | 8.9 | 95,587 | Common Stock |
| Caryn Peterson | EVP, Regulatory Affairs | Sale of securities on an exchange or to another person at price $ 8.28 per share. | 16 Mar 2022 | 6,279 | 66,172 (0%) | 0% | 8.3 | 51,978 | Common Stock |
| Laura Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.28 per share. | 16 Mar 2022 | 5,002 | 90,304 (0%) | 0% | 8.3 | 41,407 | Common Stock |
| Richard Aranda | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.28 per share. | 16 Mar 2022 | 6,278 | 211,675 (0%) | 0% | 8.3 | 51,976 | Common Stock |
| Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 650,000 | 650,000 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 190,000 | 190,000 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 265,000 | 265,000 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 190,000 | 190,000 | - | - | Stock Option (Right to Buy) | |
| Laura Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 190,000 | 190,000 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 190,000 | 190,000 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Sale of securities on an exchange or to another person at price $ 12.25 per share. | 25 Oct 2021 | 2,377 | 72,451 (0%) | 0% | 12.2 | 29,118 | Common Stock |
| Laura Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.25 per share. | 25 Oct 2021 | 2,377 | 95,306 (0%) | 0% | 12.2 | 29,118 | Common Stock |
| Richard Aranda | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.25 per share. | 25 Oct 2021 | 2,377 | 217,432 (0%) | 0% | 12.2 | 29,118 | Common Stock |
| Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2021 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Laura Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 25,000 | 97,683 (0%) | 0% | 0 | Common Stock | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 15,000 | 219,809 (0%) | 0% | 0 | Common Stock | |
| Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 47,000 | 47,000 | - | - | Stock Option (Right to Buy) | |
| Russell J. Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Thomas O. Daniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Kristina Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Joshua H. Bilenker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Renee D. Gala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Laura Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 31,750 | 31,750 | - | - | Stock Option (Right to Buy) | |
| Laura Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 10,820 | 72,683 (0%) | 0% | 0 | Common Stock | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2021 | 31,750 | 31,750 | - | - | Stock Option (Right to Buy) | |
| Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2021 | 10,820 | 74,828 (0%) | 0% | 0 | Common Stock | |
| Christian Waage | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 9.48 per share. | 23 Mar 2021 | 5,490 | 588,199 (0%) | 0% | 9.5 | 52,051 | Common Stock |
| Bryan Giraudo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.48 per share. | 23 Mar 2021 | 5,490 | 109,889 (0%) | 0% | 9.5 | 52,046 | Common Stock |
| Luisa Salter-Cid | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.48 per share. | 23 Mar 2021 | 5,491 | 206,065 (0%) | 0% | 9.5 | 52,052 | Common Stock |
| Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 162,500 | 162,500 (0%) | 0% | 0 | Common Stock | |
| Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 325,000 | 325,000 | - | - | Stock Option (Right to Buy) | |
| Christian Waage | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 45,000 | 593,689 (0%) | 0% | 0 | Common Stock | |
| Christian Waage | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Bryan Giraudo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 45,000 | 115,379 (0%) | 0% | 0 | Common Stock | |
| Luisa Salter-Cid | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Luisa Salter-Cid | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 45,000 | 211,556 (0%) | 0% | 0 | Common Stock | |
| Faheem Hasnain | Director | Purchase of securities on an exchange or from another person at price $ 10.36 per share. | 14 Oct 2020 | 96,520 | 3,478,629 (5%) | 0% | 10.4 | 999,995 | Common Stock |
| Christian Waage | EVP & General Counsel | Purchase of securities on an exchange or from another person at price $ 9.53 per share. | 14 Oct 2020 | 2,500 | 6,954 (0%) | 0% | 9.5 | 23,818 | Common Stock |
| Bryan Giraudo | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 10.01 per share. | 14 Oct 2020 | 3,000 | 7,121 (0%) | 0% | 10.0 | 30,036 | Common Stock |
| Bryan Giraudo | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 12.96 per share. | 23 Jun 2020 | 2,000 | 4,121 (0%) | 0% | 13.0 | 25,922 | Common Stock |
| Faheem Hasnain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 47,000 | 47,000 | - | - | Stock Option (right to buy) | |
| Russell J. Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Thomas O. Daniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Kristina Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Joshua H. Bilenker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Renee D. Gala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Christian Waage | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 71,500 | 71,500 | - | - | Stock Option (right to buy) | |
| Christian Waage | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 46,500 | 547,998 (0%) | 0% | 0 | Common Stock | |
| Sheila Gujrathi | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 189,500 | 189,500 (0%) | 0% | 0 | Common Stock | |
| Sheila Gujrathi | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 292,000 | 292,000 | - | - | Stock Option (right to buy) | |
| Jakob Dupont | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 71,500 | 71,500 | - | - | Stock Option (right to buy) | |
| Jakob Dupont | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 46,500 | 46,500 (0%) | 0% | 0 | Common Stock | |
| Bryan Giraudo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 46,500 | 70,379 (0%) | 0% | 0 | Common Stock | |
| Bryan Giraudo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 71,500 | 71,500 | - | - | Stock Option (right to buy) | |
| Luisa Salter-Cid | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 71,500 | 71,500 | - | - | Stock Option (right to buy) | |
| Luisa Salter-Cid | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 46,500 | 166,556 (0%) | 0% | 0 | Common Stock | |
| Luisa Salter-Cid | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 4,000 | 120,056 (0%) | 0% | 0 | Common Stock | |
| Jakob Dupont | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2019 | 40,000 | 439,317 | - | - | Non-qualified stock option (Right to Buy) | |
| Jakob Dupont | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.71 per share. | 27 Dec 2019 | 1,994 | 1,994 (0%) | 0% | 10.7 | 21,356 | Common Stock |
| Jakob Dupont | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 27 Dec 2019 | 40,000 | 0 (0%) | 0% | 15.0 | 600,004 | Common Stock |
| Jakob Dupont | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.71 per share. | 27 Dec 2019 | 40,000 | 40,000 (0%) | 0% | 10.7 | 428,400 | Common Stock |
| Jakob Dupont | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.81 per share. | 27 Dec 2019 | 1,994 | 0 (0%) | 0% | 15.8 | 31,534 | Common Stock |
| Jakob Dupont | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2019 | 1,994 | 479,317 | - | - | Non-qualified stock option (Right to Buy) | |
| Faheem Hasnain | Director | Purchase of securities on an exchange or from another person at price $ 16.80 per share. | 27 Sep 2019 | 10,000 | 3,382,109 (5%) | 0% | 16.8 | 167,980 | Common Stock |
| Christian Waage | EVP & General Counsel | Purchase of securities on an exchange or from another person at price $ 16.65 per share. | 27 Sep 2019 | 1,000 | 4,454 (0%) | 0% | 16.7 | 16,654 | Common Stock |
| Sheila Gujrathi | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 16.80 per share. | 27 Sep 2019 | 10,000 | 4,048,242 (6%) | 0% | 16.8 | 167,980 | Common Stock |
| Bryan Giraudo | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 16.78 per share. | 26 Sep 2019 | 1,121 | 2,121 (0%) | 0% | 16.8 | 18,810 | Common Stock |
| Luisa Salter-Cid | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.65 per share. | 28 Aug 2019 | 23,748 | 150,308 (0%) | 0% | 19.7 | 466,724 | Common Stock |
| Luisa Salter-Cid | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.09 per share. | 28 Aug 2019 | 26,252 | 124,056 (0%) | 0% | 20.1 | 527,319 | Common Stock |
| Otello Stampacchia | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Russell J. Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Thomas O. Daniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Kristina M. Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Joshua H. Bilenker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Renee D. Gala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 23,500 | 23,500 | - | - | Stock Option (right to buy) | |
| Bryan Giraudo | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 18.70 per share. | 30 May 2019 | 1,000 | 1,000 (0%) | 0% | 18.7 | 18,700 | Common Stock |
| Faheem Hasnain | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2019 | 43,500 | 43,500 | - | - | Stock Option (right to buy) | |
| Christian Waage | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2019 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Sheila Gujrathi | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2019 | 380,000 | 380,000 | - | - | Stock Option (right to buy) | |
| Jakob Dupont | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2019 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Bryan Giraudo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2019 | 145,000 | 145,000 | - | - | Stock Option (right to buy) | |
| Luisa Salter-Cid | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2019 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| Faheem Hasnain | Director, Executive Chairman | 12 Feb 2019 | 185,984 | 0 | - | - | Series A Preferred Stock | ||
| Faheem Hasnain | Director, Executive Chairman | 12 Feb 2019 | 58,599 | 3,372,109 (5%) | 0% | - | Common Stock | ||
| Faheem Hasnain | Director, Executive Chairman | 12 Feb 2019 | 77,719 | 0 | - | - | Series B Preferred Stock | ||
| Russell J. Cox | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 12 Feb 2019 | 7,200 | 7,200 (0%) | 0% | 16 | 115,200 | Common Stock |
| Christian Waage | EVP & General Counsel | 12 Feb 2019 | 15,543 | 0 | - | - | Series B Preferred Stock | ||
| Christian Waage | EVP & General Counsel | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 12 Feb 2019 | 1,550 | 501,498 (0%) | 0% | 16 | 24,800 | Common Stock |
| Christian Waage | EVP & General Counsel | 12 Feb 2019 | 3,454 | 3,454 (0%) | 0% | - | Common Stock | ||
| Thomas O. Daniel | Director | 12 Feb 2019 | 171,429 | 0 | - | - | Series A Preferred Stock | ||
| Thomas O. Daniel | Director | 12 Feb 2019 | 38,095 | 38,095 (0%) | 0% | - | Common Stock | ||
| Sheila Gujrathi | Director, President & CEO | 12 Feb 2019 | 55,957 | 0 | - | - | Series B Preferred Stock | ||
| Sheila Gujrathi | Director, President & CEO | 12 Feb 2019 | 62,030 | 4,038,242 (6%) | 0% | - | Common Stock | ||
| Sheila Gujrathi | Director, President & CEO | 12 Feb 2019 | 223,182 | 0 | - | - | Series A Preferred Stock | ||
| Kristina M. Burow | Director | 12 Feb 2019 | 16,571,429 | 0 | - | - | Series A Preferred Stock | ||
| Kristina M. Burow | Director | 12 Feb 2019 | 345,419 | 4,027,958 (6%) | 0% | - | Common Stock | ||
| Kristina M. Burow | Director | 12 Feb 2019 | 1,554,388 | 0 | - | - | Series B Preferred Stock | ||
| Kristina M. Burow | Director | 12 Feb 2019 | 1,554,388 | 0 | - | - | Series B Preferred Stock | ||
| Kristina M. Burow | Director | 12 Feb 2019 | 16,571,428 | 0 | - | - | Series A Preferred Stock | ||
| Kristina M. Burow | Director | 12 Feb 2019 | 3,682,539 | 3,682,539 (6%) | 5% | - | Common Stock | ||
| Kristina M. Burow | Director | 12 Feb 2019 | 345,419 | 4,027,958 (6%) | 0% | - | Common Stock | ||
| Kristina M. Burow | Director | 12 Feb 2019 | 3,682,539 | 3,682,539 (6%) | 5% | - | Common Stock | ||
| Bryan Giraudo | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 12 Feb 2019 | 6,000 | 23,879 (0%) | 0% | 16 | 96,000 | Common Stock |
| Bryan Giraudo | Chief Financial Officer | 12 Feb 2019 | 17,879 | 17,879 (0%) | 0% | - | Common Stock | ||
| Bryan Giraudo | Chief Financial Officer | 12 Feb 2019 | 57,142 | 0 | - | - | Series A Preferred Stock | ||
| Bryan Giraudo | Chief Financial Officer | 12 Feb 2019 | 23,316 | 0 | - | - | Series B Preferred Stock |